Biotech News

Olema Oncology to Present Combination Data from the Palazestrant and OP-3136 Programs at the 2026 San Antonio Breast Cancer Symposium

Olema Pharmaceuticals, Inc. (OLMA)Olema Pharmaceuticals, Inc.Company update

SAN FRANCISCO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it

Related news

OLMAOlema Pharmaceuticals, Inc.2026-11-10 12:00 EST

Olema Oncology Reports Third Quarter 2026 Financial and Operating Results

OLMAOlema Pharmaceuticals, Inc.2026-11-18 07:30 EST

Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR Symposium

BNTXBioNTech2026-10-19 10:45 EST

BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026

PRLDPrelude Therapeutics2026-10-13 11:01 EST

Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer

KURAKura Oncology2026-11-04 14:02 EST

Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026

BNTXBioNTech2026-10-22 10:45 EST

BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer

RVMDRevolution Medicines2026-10-20 12:00 EST

Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer

TEVATeva Pharmaceutical Industries2026-11-20 21:30 EST

Teva to Present at the 9th Annual Evercore Healthcare Conference, the Piper Sandler 38th Annual Healthcare Conference and Citi’s 2026 Global Healthcare Conference

NRIXNurix Therapeutics2026-11-05 12:00 EST

Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

ERASErasca2026-11-04 13:30 EST

Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015

Olema Pharmaceuticals, Inc.

Endocrine-Driven Cancer Company Olema Oncology develops targeted therapies based on estrogen receptor biology, nuclear receptors, and resistance mechanisms in breast cancer. Palazestrant Palazestrant is an oral complete estrogen receptor antagonist being studied as monotherapy and in combinations for ER-positive, HER2-negative breast...

Recent company news

Stock data

Close
7.15 USD
Market cap
933.74M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States